GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Scilex Holding Company
The shares of Scilex, a biopharmaceutical company focused on pain treatment, reflect its efforts to commercialize its products. The price trajectory is volatile and depends on FDA decisions, partnerships, and the company's ability to compete in the challenging pain relief market.
Share prices of companies in the market segment - Neuro
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid drugs for the treatment of acute and chronic pain. We have classified it in the Neurology segment. The chart below shows how the market values companies fighting the opioid crisis.
Broad Market Index - GURU.Markets
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid medications for the treatment of acute and chronic pain. As a component of the GURU.Markets index, it is fighting the opioid crisis. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SCLX - Daily change in the company's share price Scilex Holding Company
The change_co indicator for Scilex, a pharmaceutical company, measures its high volatility. It reflects its sensitivity to sales of its pain medications and development news. This indicator is a key element in the formulas on System.GURU.Markets for analyzing the pharmaceutical sector.
Daily change in the price of a set of shares in a market segment - Neuro
Scilex Holding Company is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to SCLX, which focuses on painkillers, helps understand its unique risk profile related to regulatory issues.
Daily change in the price of a broad market stock, index - GURU.Markets
Scilex Holding specializes in developing non-addictive painkillers. Given the severity of the opioid crisis, its developments are attracting considerable attention. The company's shares are volatile and dependent on research progress, contributing to market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Scilex Holding Company
For Scilex Holding Company, year-over-year performance tells the story of its pain management portfolio. Its market capitalization change over the past 12 months reflects sales of its approved products, such as the lidocaine patch, as well as progress in developing new non-opioid painkillers, which meets a huge market need.
Annual dynamics of market capitalization of the market segment - Neuro
Scilex Holding Company is a commercial pharmaceutical company focused on non-opioid pain medications. This chart shows how its unique technology, competition, and the complex regulatory environment in the pain relief market impact its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Scilex, specializing in pain medications, operates in a complex and highly regulated niche. Its stock price is driven not by the economy, but by sales volume, generic competition, and lawsuits. The chart is a complex story, intertwining medical, legal, and social factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Scilex Holding Company
Scilex Holding Company (Neuro)'s market value fluctuates monthly due to news about pharmaceutical developments and clinical trial results. As a company focused on pain management, its market capitalization, as reflected in the chart, is sensitive to operating cycles related to patenting, partnerships, and, most importantly, the company's readiness to bring new non-opioid drugs to market.
Monthly dynamics of market capitalization of the market segment - Neuro
Scilex Holding Company is a pharmaceutical company focused on the development and commercialization of non-opioid painkillers. This niche is extremely relevant amid the opioid crisis. The dynamics of the pharmaceutical sector underscore the overall context in which Scilex strives to offer the market safer and more effective solutions for the treatment of acute and chronic pain.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Scilex Holding Company is a commercial pharmaceutical company focused on the development and sale of non-opioid pain relievers. Its business sits at the intersection of the enormous need for pain treatment and the opioid crisis. The broader market graph allows us to assess the demand for its unique products in this complex and regulated market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Scilex Holding Company
Scilex Holding Company is a pharmaceutical company focused on non-opioid pain treatments. Its weekly stock price is driven by sales reports for its approved products and news about clinical trials of new painkillers.
Weekly dynamics of market capitalization of the market segment - Neuro
Scilex Holding specializes in pain medications, particularly neuropathic pain. This is a large market with high competition and regulatory pressure. Compare the company's weekly performance with the pharmaceutical sector to understand how the market perceives the potential of its products against the backdrop of general industry risks.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Scilex specializes in pain medications. The pharmaceutical sector is considered "defensive," but Scilex shares can be volatile due to intense competition and drug news. The chart shows how these factors impact its performance relative to the market.
Market capitalization of the company, segment and market as a whole
SCLX - Market capitalization of the company Scilex Holding Company
Scilex Holding's market capitalization reflects its focus on developing and commercializing non-opioid painkillers. Its volatile chart reflects how investors view its product portfolio in the context of the opioid crisis. This is a bet that its drugs will become a sought-after alternative to traditional painkillers.
SCLX - Share of the company's market capitalization Scilex Holding Company within the market segment - Neuro
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. Its market share reflects the potential of its products to combat the opioid crisis. The chart shows the company's complex journey in its quest to offer new solutions for the treatment of acute and chronic pain.
Market capitalization of the market segment - Neuro
Below is a chart of the overall market capitalization of the pharmaceutical sector. Scilex Holding specializes in pain treatment, specifically with its lidocaine patch. This market is vast, but also highly competitive. Scilex is seeking to carve out its niche by offering non-opioid solutions for chronic pain relief.
Market capitalization of all companies included in a broad market index - GURU.Markets
Scilex Holding is a pharmaceutical company specializing in the development and commercialization of non-opioid painkillers. Its market capitalization is a bet on combating the opioid crisis. The chart below shows the economic weight of companies solving this pressing problem.
Book value capitalization of the company, segment and market as a whole
SCLX - Book value capitalization of the company Scilex Holding Company
Scilex's book value is derived from its portfolio of commercialized pain medications, as well as assets acquired from its parent company, Sorrento. The graph tells the complex story of a company trying to build its business on already approved products while simultaneously navigating a complex corporate legacy and debt obligations.
SCLX - Share of the company's book capitalization Scilex Holding Company within the market segment - Neuro
Scilex Holding is involved in pain treatment. The chart shows its share of real assets. These include its production facilities, where patches and other medications are manufactured, as well as the commercial infrastructure for their marketing.
Market segment balance sheet capitalization - Neuro
Scilex Holding, a pharmaceutical company, focuses on commercialization, making it less capital-intensive than giants with dozens of factories. The graph below illustrates the scale of the pharmaceutical sector, highlighting its business model.
Book value of all companies included in the broad market index - GURU.Markets
Scilex Holding is a pharmaceutical company focused on pain treatment. Its assets include drug rights and commercial infrastructure. Its stake in BCap_All provides the financial base that allows it to commercialize non-opioid painkillers, addressing one of the most pressing healthcare challenges.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Scilex Holding Company
Scilex Holding is a pharmaceutical company. Its valuation is below book value, reflecting its complex corporate history, high debt, and investor doubts about the commercial success of its pain treatment products.
Market to book capitalization ratio in a market segment - Neuro
Scilex Holding is a pharmaceutical company specializing in pain treatment. This metric reflects the extent to which its market valuation, based on its portfolio of approved products and developments, exceeds the value of its tangible assets. It is an assessment of its commercial potential in the pain relief market.
Market to book capitalization ratio for the market as a whole
Scilex Holding is a pharmaceutical company specializing in non-opioid painkillers. This is a critical area with huge demand. This chart helps understand how the market values companies offering solutions to serious social and medical problems and the premium placed on their innovations.
Debts of the company, segment and market as a whole
SCLX - Company debts Scilex Holding Company
Scilex Holding, a biopharmaceutical company specializing in non-opioid painkillers, uses capital to advance its products. Its debt strategy is aimed at funding the marketing and sales of already approved drugs, as well as conducting clinical trials to expand their indications, which requires significant investment.
Market segment debts - Neuro
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid painkillers. This is a socially significant yet complex area. This chart shows the company's financial strategy for bringing its innovative products to market, aiming to offer alternatives to traditional analgesics.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Scilex Holding Company
Scilex Holding develops and commercializes non-opioid painkillers. The pharmaceutical business requires significant expenditures on R&D and drug promotion. This chart shows the company's debt-to-equity ratio, giving investors insight into the company's financial strategy and its reliance on creditors to achieve profitability.
Market segment debt to market segment book capitalization - Neuro
Scilex Holding Company specializes in the development and commercialization of non-opioid painkillers. This chart shows debt trends in the pharmaceutical sector. It allows one to assess how the company finances its products amid the acute problem of opioid addiction and how its debt strategy compares to other players in the painkiller market.
Debt to book value of all companies in the market
Scilex Holding Company specializes in the development and commercialization of non-opioid painkillers. The pharmaceutical business, especially at the product launch stage, requires significant marketing expenditures. This total debt burden chart allows us to assess whether Scilex leverages its commercial activities, following overall market trends, or pursues a different strategy.
P/E of the company, segment and market as a whole
P/E - Scilex Holding Company
Scilex Holding Company specializes in the development and commercialization of non-opioid painkillers. This chart shows how the market evaluates its product portfolio in the context of the opioid crisis. This evaluation depends on the success of its products and its ability to offer effective and safe alternatives to traditional analgesics.
P/E of the market segment - Neuro
This chart of pharmaceutical companies serves as a benchmark for Scilex Holding. It reflects how investors, on average, value the sector. Comparisons with this chart help us understand whether Scilex's focus on developing non-opioid painkillers is seen as more or less promising than other pharmaceutical companies operating in more traditional fields.
P/E of the market as a whole
Scilex Holding is a pharmaceutical company focused on pain medications, primarily non-opioid ones. This niche is socially significant. This chart of general sentiment in the pharmaceutical industry helps us understand how investors view the commercial potential of these drugs and whether they believe they can displace traditional painkillers.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Scilex Holding Company
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. This graph reflects expectations for the fight against the opioid crisis. The assessment is based on sales volumes of its existing products and success in developing new, safer alternatives for the treatment of acute and chronic pain.
%20P%2FE%20Scilex%20Holding%20Company&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Scilex-Holding-Company&v=1772676287507 "Chart of the company's future (projected) P/E Scilex Holding Company")
Future (projected) P/E of the market segment - Neuro
Scilex Holding is a biopharmaceutical company focused on developing and commercializing non-opioid painkillers. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess how the market views its efforts to develop alternatives to traditional painkillers amid the opioid crisis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772676287528 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. Despite the general market fluctuations illustrated by this chart, Scilex's business is driven by medical needs. Growing demand for effective and safe alternatives to opioids is the company's main long-term driver.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772676287547 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Scilex Holding Company
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. This is a pressing issue amid the opioid crisis. This chart shows the company's financial results as it strives to offer safer alternatives for pain treatment.
Profit of companies in the market segment - Neuro
Scilex Holding is a pharmaceutical company specializing in non-opioid pain treatments. This chart shows profitability in the neuroscience sector. For SCLX, this reflects the pressing social problem of opioid addiction. Demand for their products is driven by the search for safer and more effective ways to manage chronic pain.
Overall market profit
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid painkillers. This is a socially significant task in light of the opioid crisis. The company's success depends on its product portfolio and sales performance. This overall profitability chart does not reflect the specifics and needs of the painkiller market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Scilex Holding Company
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid painkillers. The profit forecast presented here depends on sales of its already approved products, such as the ZTlido patch, and the success of its developments in clinical trials. This is a look at the future of the pain treatment market.
%20profit%20of%20the%20company%20Scilex%20Holding%20Company&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Scilex-Holding-Company&v=1772676287595 "Graph of future (projected) profit of the company Scilex Holding Company")
Future (predicted) profit of companies in the market segment - Neuro
Scilex Holding Company specializes in non-opioid pain treatments. The profit forecast for this sector depends on success in combating acute and chronic pain without the use of addictive medications. This chart reflects analysts' expectations for the future of the painkiller market, where there is a huge need for safer alternatives.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772676287638 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Scilex Holding is a pharmaceutical company specializing in non-opioid painkillers. Its success depends on demand for alternatives to traditional analgesics. The revenue projections presented here impact healthcare budgets, which determine reimbursement and availability of new medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772676287671 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Scilex Holding Company
Scilex Holding is a pharmaceutical company focused on non-opioid pain treatments. This chart shows how the market values its revenue, which is determined by sales of its approved products. Given the opioid crisis in the US, its focus on alternative painkillers is a key factor investors factor into its valuation.
P/S market segment - Neuro
Scilex Holding is a pharmaceutical company specializing in the development and commercialization of non-opioid painkillers. This is an important and socially significant niche. This chart shows the average revenue estimate for the sector, which helps understand how the market views Scilex's product portfolio and commercial prospects.
P/S of the market as a whole
Scilex Holding is a pharmaceutical company specializing in the development and commercialization of non-opioid pain medications. The company aims to offer an alternative to traditional pain treatments. Its success depends on sales of its products. This chart provides a general market backdrop for assessing investor sentiment regarding revenue prospects in this important segment of the pharmaceutical market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Scilex Holding Company
Scilex Holding Company is a pharmaceutical company specializing in the development and commercialization of non-opioid painkillers. This chart shows how investors estimate the company's future sales, reflecting the urgent need for effective and safe alternatives to opioids.
%20P%2FS%20Scilex%20Holding%20Company&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Scilex-Holding-Company&v=1772676287730 "The graph of the company's future (projected) P/S Scilex Holding Company")
Future (projected) P/S of the market segment - Neuro
Scilex Holding Company is a pharmaceutical company specializing in non-opioid pain medications. Its goal is to offer effective and safe alternatives for chronic pain. This chart shows how the market views its product portfolio in the context of the opioid crisis and the need for new treatments.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772676287755 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Scilex Holding Company is a pharmaceutical company specializing in non-opioid painkillers. Their goal is to offer alternatives for the treatment of acute and chronic pain. This chart, reflecting the state of the healthcare system, is important. Economic stability provides funding for the development and launch of new, safer painkillers.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772676287757 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Scilex Holding Company
Scilex Holding specializes in the development and commercialization of non-opioid pain medications. This chart shows the revenue from sales of its approved products. Revenue growth demonstrates the company's success in offering alternative solutions for the treatment of acute and chronic pain, a significant medical problem.
Sales of companies in the market segment - Neuro
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid painkillers. Their goal is to provide patients with effective solutions for acute and chronic pain without the risk of addiction. Their revenue is generated by sales of their already approved and marketed drugs.
Overall market sales
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. Its goal is to provide patients with chronic pain with effective and safe alternatives. This total revenue chart includes the healthcare sector, where SCLX is working to address the pressing problem of opioid addiction.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Scilex Holding Company
Scilex Holding is a pharmaceutical company focused on medications for the treatment of acute and chronic pain. This chart shows analysts' expectations for sales of its non-opioid painkillers, which is especially relevant in light of the opioid crisis.
%20sales%20of%20the%20company%20Scilex%20Holding%20Company&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Scilex-Holding-Company&v=1772676287821 "Schedule of future (projected) sales of the company Scilex Holding Company")
Future (projected) sales of companies in the market segment - Neuro
Scilex Holding is a pharmaceutical company specializing in the development and commercialization of non-opioid painkillers. This chart shows forecasts for the entire pain medication market. It reflects the urgent need for effective and safe alternatives to opioids to combat chronic pain, which is the company's mission.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772676287831 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Scilex Holding Company, a pain management company, sees this graph as a reflection of the needs of an aging population and the state of healthcare. Rising overall economic forecasts provide funding for the development and promotion of non-opioid painkillers. This is an important social and medical issue that Scilex addresses.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772676287838 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Scilex Holding Company
Scilex Holding Company is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. Its profitability depends on the successful sales of existing products and the advancement of new developments. This chart shows how effectively the company monetizes its portfolio of medications for the treatment of acute and chronic pain.
Market segment marginality - Neuro
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid painkillers. This indicator reflects the commercial success of its products. This high result indicates a significant need for effective and safe alternatives to opioids.
Market marginality as a whole
Scilex Holding is a pharmaceutical company focused on pain medications. Its success depends on sales of existing products and the approval of new ones. This overall profitability curve has little impact on the specific pain relief market, where patents, competition, and regulatory decisions play a key role.
Employees in the company, segment and market as a whole
Number of employees in the company Scilex Holding Company
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. This chart shows the team marketing patches and gels for neuropathic pain, offering physicians and patients effective and safer alternatives to traditional analgesics.
Share of the company's employees Scilex Holding Company within the market segment - Neuro
Scilex Holding Company is a pharmaceutical company focused on the development and commercialization of non-opioid pain medications. Amid the opioid crisis, its mission is especially important. Promoting new medications requires a strong sales team, and this chart reflects its growing commercial reach in this therapeutic area.
Number of employees in the market segment - Neuro
Scilex Holding is a pharmaceutical company specializing in pain treatment, particularly neuropathic pain. This chart shows the team developing and marketing non-opioid analgesics, a critical task in light of the opioid crisis. Their work is aimed at creating safer and more effective pain relief methods.
Number of employees in the market as a whole
Scilex Holding Company specializes in the development and commercialization of non-opioid painkillers. The overall economic health, as measured by employment trends, influences the market for these medications. A strong labor market ensures funding for the healthcare system, which facilitates the implementation of new, safer pain treatments, reducing opioid dependence.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Scilex Holding Company (SCLX)
Scilex Holding Company is a pharmaceutical company specializing in non-opioid painkillers. This chart shows how the market values their products in light of the opioid crisis. The high market capitalization per employee may reflect the significant market demand for their solutions and the value of their patent portfolio, which was developed by a small team.
%20of%20the%20company%20Scilex%20Holding%20Company%20(SCLX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Scilex-Holding-Company-SCLX&v=1772676288012 "Chart of market capitalization per employee (in thousands of dollars) of the company Scilex Holding Company (SCLX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Scilex Holding Company specializes in the development and commercialization of non-opioid painkillers. In the pharmaceutical industry, a company's value is determined by its product portfolio and research. This chart shows the market valuation of its assets and intellectual property per employee compared to other players in the sector.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772676288036 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Scilex Holding is a pharmaceutical company focused on the development and commercialization of non-opioid painkillers. In light of the opioid crisis, this metric reflects the enormous social and commercial significance of its mission. It demonstrates how the market values its products, which can help combat pain without the risk of addiction.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772676288054 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Scilex Holding Company (SCLX)
Scilex Holding is a pharma company focused on pain management, primarily non-opioid options. Their main product is the ZTlido patch. This chart shows how effectively their sales team can promote their products to doctors. Effectiveness depends on prescription volume and insurance coverage.
%20Chart%20Scilex%20Holding%20Company%20(SCLX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Scilex-Holding-Company-SCLX&v=1772676288064 "Company Profit Per Employee (in thousands of dollars) Chart Scilex Holding Company (SCLX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Scilex Holding Company is a pharmaceutical company focused on pain management, particularly acute and chronic pain. Their portfolio includes patches (Ztlido) and other non-opioid solutions. This chart represents an industry benchmark. In the pharmaceutical industry, particularly in the sensitive field of pain management, it reflects how successfully the Scilex team (R&D, sales) promotes its products to physicians.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772676288093 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Scilex Holding (SCLX) is a pharmaceutical company focused on pain management, primarily non-opioid. Their products include lidocaine patches (Ztlido) and other non-opioid analgesics. Their strength lies in commercialization. This chart shows how effectively their sales team (medical representatives) can sell these drugs to doctors.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772676288100 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Scilex Holding Company (SCLX)
Scilex Holding is a pharmaceutical company focused on pain management. This chart shows its commercial performance. Revenue per employee is generated by sales of non-opioid pain relief products, such as the ZTlido patch. Growth in this metric will depend on increased market penetration and the success of new products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Scilex-Holding-Company-SCLX&v=1772676288110 "Sales chart per company employee Scilex Holding Company (SCLX)")
Sales per employee in the market segment - Neuro
Scilex Holding (SCLX) is a pharmaceutical company focused on pain management, primarily non-opioid therapies (patches, gels). It is commercially active, but with niche products. This chart shows how effective their commercial team (sales, marketing) is in generating revenue per employee in the highly competitive pain management sector.
Sales per employee for the market as a whole
Scilex is a pharmaceutical company focused on non-opioid painkillers. Their products include lidocaine patches (Ztlido) and oral medications. This chart shows how effectively their sales team generates revenue by selling these specialized pain medications.
Short shares by company, segment and market as a whole
Shares shorted by company Scilex Holding Company (SCLX)
Scilex (SCLX) is a pharmaceutical company specializing in non-opioid pain treatments, including patches and gels (Ztlido). This chart measures bearish sentiment. The high short interest may be due to the company's complex corporate history (its connection with Sorrento), the highly competitive pain market, and concerns about the commercial success of its products.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Scilex-Holding-Company-SCLX&v=1772676288163 "Short Shares Chart for the Company Scilex Holding Company (SCLX)")
Shares shorted by market segment - Neuro
Scilex (SCLX) is a pharmaceutical company specializing in non-opioid pain treatments, including patches and injections. This chart reflects the overall sentiment in the pharmaceutical sector. It shows how many investors anticipate challenges in this niche, possibly due to regulatory hurdles.
Shares shorted by the overall market
Scilex Holding (SCLX) is focused on non-opioid pain medications. This might seem like a non-discretionary expense. But SCLX is not a giant, but a growing company. When this market fear indicator rises, investors sell off the "second tier" of pharma, fearing financing risks and fierce competition in a recessionary environment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Scilex Holding Company (SCLX)
Scilex Holding (SCLX) is a pharmaceutical company (spinned out of Sorrento) focused on non-opioid pain medications. This chart measures how investors view its commercial prospects. It shows when the stock is overbought on sales growth expectations or oversold due to a challenging corporate history.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Scilex-Holding-Company-SCLX&v=1772676288183 "RSI 14 indicator chart for the company's stock Scilex Holding Company (SCLX)")
RSI 14 Market Segment - Neuro
Scilex Holding is a biopharmaceutical company (spinned out of Sorrento) focused on pain treatment, primarily non-opioid therapies. Their key products are ZTlido (a lidocaine patch) and Gloperba. This chart reflects the overall sentiment in the neuroscience sector, helping to gauge the overall market sentiment toward this speculative industry.
RSI 14 for the overall market
Scilex (SCLX), a pharmaceutical company focused on pain treatment. This chart reflects the mood in the sector. During periods of euphoria, investors are willing to fund R&D. In times of panic, they seek companies with existing sales. SCLX, with both, may be more stable than pure biotechs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SCLX (Scilex Holding Company)
Scilex Holding is a pharmaceutical company focused on the treatment of acute and chronic pain without the use of opioids. Its key products are the ZTlido patch and gout medications. This chart shows the average price target from analysts assessing sales growth for these non-additive painkillers.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SCLX-Scilex-Holding-Company&v=1772676288191 "A chart showing analyst consensus forecasts for the expected stock price. SCLX (Scilex Holding Company)")
The difference between the consensus estimate and the actual stock price SCLX (Scilex Holding Company)
Scilex is a pharmaceutical company (a spinoff of Sorrento) focused on pain treatment. Their main commercial product is ZTlido (a lidocaine patch). They are also developing non-opioid painkillers. This chart shows how analysts assess their commercial success and their complex, controversial R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SCLX-Scilex-Holding-Company&v=1772676288193 "A chart showing the difference between the consensus forecast and the actual stock price. SCLX (Scilex Holding Company)")
Analyst consensus forecast for stock prices by market segment - Neuro
Scilex (SCLX) is a pharmaceutical company focused on non-opioid treatments for acute and chronic pain (e.g., the ZTlido patch). This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe demand for "safe" painkillers will grow.
Analysts' consensus forecast for the overall market share price
Scilex Holding is a biopharmaceutical company specializing in pain treatment, specifically non-opioid analgesics (patches, gels). This chart shows overall market sentiment. For Scilex, operating in a complex and highly regulated field (pain treatment), overall optimism is important, but their success depends more on regulatory approval and physician acceptance of their products.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Scilex Holding Company
Scilex is a pharmaceutical company focused on non-opioid pain management. Their commercial products include non-invasive solutions such as ZTlido (a lidocaine patch) and Gloperba (liquid colchicine). This chart summarizes their commercialization progress, reflecting their ability to grow sales of these niche, yet safer, pain medications.
AKIMA Market Segment Index - Neuro
Scilex Holding is a pharmaceutical company specializing in non-opioid pain treatments for both acute and chronic pain. This chart shows the average index for the neurosurgical segment. It allows investors to assess how Scilex, which is working on the critical issue of pain management, is performing relative to the industry average.
The AKIM Index for the overall market
Scilex Holding is a biopharmaceutical company focused on non-opioid pain treatments (patches, gels). It was spun out of Sorrento. This chart, which reflects the market average, provides a macro backdrop. It helps assess how SCLX, which is commercializing its products in a competitive environment, compares to overall economic trends.
